Spyre Therapeutics
NASDAQ · SYRE·Waltham, MA·Mid-cap·Phase 2
Clinical-stage biotech advancing extended half-life antibodies and rational combinations for inflammatory bowel disease. Portfolio includes targets α4β7 (SPY001), TL1A (SPY002), IL-23 (SPY003), and a rational combination (SPY004) in Phase 2 for ulcerative colitis and Crohn's disease.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Spyre Therapeutics Corporate Overview | Corporate overview | April 11, 2026 | 38 |